Inventor · disambiguated record
Jon E. Chatterton
Also filed as: CHATTERTON JON E · CHATTERTON JON EDWARD
54 granted patents·60 pending applications·241 citations·filing 2001–2025
98Inventor score
Files withALCON RES LTD28ARROWHEAD PHARMACEUTICALS INC24ARROWHEAD RES CORP15CHATTERTON JON E11PREC BIOSCIENCES INC7
Top patents by PatentIndex Score
114 records- 0197US8940887B2RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesisALCON RES LTD·Filed 2013·Granted Jan 27, 2015·31 cites·2 claims
- 0297US8268798B2Low density lipoprotein receptor-mediated siRNA deliveryCHATTERTON JON E·Filed 2011·Granted Sep 18, 2012·34 cites·10 claims
- 0395US7947660B2RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucomaALCON INC·Filed 2006·Granted May 24, 2011·31 cites·18 claims
- 0494US8173617B2RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucomaCLARK ABBOT F·Filed 2011·Granted May 8, 2012·31 cites·17 claims
- 0593US7973019B1Transferrin/transferrin receptor-mediated siRNA deliveryALCON RES LTD·Filed 2008·Granted Jul 5, 2011·16 cites·13 claims
- 0693US7879813B2Interfering RNA delivery system and uses thereofALCON RES LTD·Filed 2008·Granted Feb 1, 2011·16 cites·11 claims
- 0793US7592324B2RNAi-mediated inhibition of ocular targetsALCON INC·Filed 2006·Granted Sep 22, 2009·26 cites·37 claims
- 0891US11384335B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2021·Granted Jul 12, 2022·1 cites·3 claims
- 0990US11453861B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2022·Granted Sep 27, 2022·1 cites·8 claims
- 1090US11008548B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2020·Granted May 18, 2021·2 cites·3 claims
- 1189US11186822B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2021·Granted Nov 30, 2021·1 cites·3 claims
- 1289US8399653B2Transferrin/transferrin receptor-mediated siRNA deliveryCHATTERTON JON E·Filed 2011·Granted Mar 19, 2013·8 cites·6 claims
- 1386US9289514B2Low density lipoprotein receptor-mediated siRNA deliveryARROWHEAD RES CORP·Filed 2014·Granted Mar 22, 2016·4 cites·14 claims
- 1486US8222227B2RNAi-mediated inhibition of histamine receptor H1-related conditionsYANNI JOHN M·Filed 2011·Granted Jul 17, 2012·6 cites·13 claims
- 1585US8017592B2RNAi-mediated inhibition of histamine receptor H1-related conditionsALCON RES LTD·Filed 2007·Granted Sep 13, 2011·5 cites·13 claims
- 1685US2022364097A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1784US9526799B2Low density lipoprotein receptor-mediated siRNA deliveryARROWHEAD RES CORP·Filed 2016·Granted Dec 27, 2016·2 cites·12 claims
- 1884US7732421B2RNAI-mediated inhibition of tumor necrosis factor α-related conditionsALCON RES LTD·Filed 2007·Granted Jun 8, 2010·4 cites·12 claims
- 1984US2024084252A1Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)PREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2083US8937051B2Low density lipoprotein receptor-mediated siRNA deliveryALCON RES LTD·Filed 2013·Granted Jan 20, 2015·3 cites·16 claims
- 2183US8664375B2Interfering RNA delivery system and uses thereofCHATTERTON JON E·Filed 2010·Granted Mar 4, 2014·4 cites·8 claims
- 2283US2022162614A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2382US8048863B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsALCON RES LTD·Filed 2007·Granted Nov 1, 2011·3 cites·36 claims
- 2482US2022042021A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2581US11851680B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2022·Granted Dec 26, 2023·0 cites·3 claims
- 2681US7981870B2RNAi-mediated inhibition of H1F1A for treatment of ocular angiogenesisALCON RES LTD·Filed 2010·Granted Jul 19, 2011·2 cites·12 claims
- 2779US9206428B2RNAi-mediated inhibition of histamine receptor H1-related conditionsARROWHEAD RES CORP·Filed 2013·Granted Dec 8, 2015·2 cites·17 claims
- 2879US2021230603A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2979US2021108206A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3078US9476047B2RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditionsARROWHEAD RES CORP·Filed 2015·Granted Oct 25, 2016·1 cites·13 claims
- 3178US8618278B2RNAi-mediated inhibition of histamine receptor H1-related conditionsYANNI JOHN M·Filed 2012·Granted Dec 31, 2013·2 cites·4 claims
- 3278US2020392508A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3377US8673873B1RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disordersYANNI JOHN M·Filed 2009·Granted Mar 18, 2014·1 cites·6 claims
- 3477US2020277608A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3576US2020165615A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3675US9562230B2Transferrin/transferrin receptor-mediated siRNA deliveryARROWHEAD RES CORP·Filed 2015·Granted Feb 7, 2017·1 cites·11 claims
- 3775US9233170B2Interfering RNA delivery system and uses thereofARROWHEAD RES CORP·Filed 2014·Granted Jan 12, 2016·1 cites·12 claims
- 3875US8569258B2Low density lipoprotein receptor-mediated siRNA deliveryCHATTERTON JON E·Filed 2012·Granted Oct 29, 2013·1 cites·12 claims
- 3975US2019338287A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4075US2020048637A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4174US2019256854A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4273US2019144866A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4373US2019071676A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4473US2025154460A1Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)PREC BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4571US2015167002A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISALCON RES LTD·Filed 2014·Application pending·0 cites
- 4670US9173896B2RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditionsCHATTERTON JON E·Filed 2009·Granted Nov 3, 2015·0 cites·14 claims
- 4768US9347062B2Interfering RNA delivery system and uses thereofARROWHEAD RES CORP·Filed 2014·Granted May 24, 2016·0 cites·7 claims
- 4868US2009275641A1RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular DisordersALCON RES LTD·Filed 2009·Application pending·0 cites
- 4968US2017198294A1RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESISARROWHEAD PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 5068US2009131358A1LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERYALCON RES LTD·Filed 2008·Application pending·0 cites
Showing the top 50 of 114 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jon E. Chatterton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →